No Data
NEP INTERLONG: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024
What does AI pharmaceuticals still lack before a market explosion? | Focus
① From the discovery of targets to the identification of preclinical candidate compounds, current generative AI mainly focuses on the early stages of drug development, which can lead to significant acceleration; ② If AI in drug development is to further expand the realm of possibilities, it must explore more profitable real-world applications.
NEP INTERLONG: 2024 INTERIM REPORT
NEP Interlong (08329) released its interim performance report, with a net profit attributable to shareholders of HKD 37.907 million, an increase of 26.86% year-on-year.
nep interlong (08329) announced its performance for the 6 months ended June 30, 2024, during which the group achieved revenue...
Express News | Shenzhen Neptunus Interlong Bio-Technique H1 Gross Margin 36%
NEP INTERLONG: ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024
